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Abstract
A causal role of mutations in multiple general transcription factors in neurodevelopmental disorders including autism
suggested that alterations in global levels of gene expression regulation might also relate to disease risk in sporadic cases of
autism. This premise can be tested by evaluating for changes in the overall distribution of gene expression levels. For
instance, in mice, variability in hippocampal-dependent behaviors was associated with variability in the pattern of the
overall distribution of gene expression levels, as assessed by variance in the distribution of gene expression levels in the
hippocampus. We hypothesized that a similar change in variance might be found in children with autism. Gene expression
microarrays covering greater than 47,000 unique RNA transcripts were done on RNA from peripheral blood lymphocytes
(PBL) of children with autism (n=82) and controls (n=64). Variance in the distribution of gene expression levels from each
microarray was compared between groups of children. Also tested was whether a risk factor for autism, increased paternal
age, was associated with variance. A decrease in the variance in the distribution of gene expression levels in PBL was
associated with the diagnosis of autism and a risk factor for autism, increased paternal age. Traditional approaches to
microarray analysis of gene expression suggested a possible mechanism for decreased variance in gene expression. Gene
expression pathways involved in transcriptional regulation were down-regulated in the blood of children with autism and
children of older fathers. Thus, results from global and gene specific approaches to studying microarray data were
complimentary and supported the hypothesis that alterations at the global level of gene expression regulation are related
to autism and increased paternal age. Global regulation of transcription, thus, represents a possible point of convergence
for multiple etiologies of autism and other neurodevelopmental disorders.
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Introduction
Autism is a severe neurodevelopmental disorder with character-
istic social and communication deficits and ritualistic or repetitive
behaviors that appear by age three. Many etiologies have been
suggested and numerous risk factors have been identified [1].
Though autism is associated with a high degree of heritability, few
specific genetic mutations have been identified accounting for a
minority of cases [2,3,4,5,6], while the majority of cases are
consideredsporadic. The failureto identify specificgene variants for
most cases of autism has been attributed to many potential factors
including complex interactions of multiple genes, a heterogeneous
disorder with multiple causes converging on the autistic phenotype,
or epigenetic factors not related to specific genetic mutations or
polymorphisms [2,3]. None of these hypotheses has been confirmed
and they are not mutually exclusive.
Research on gene expression in autism has previously focused
on identifying specific or a limited group of genes related to disease
[7,8,9]. The idea that alterations at the global level of gene
expression regulation might be important in mediating the risk for
autism or other disease states has been largely underexplored.
Supporting the possible importance of global regulation of gene
expression in neurodevelopmental disorders, genetic studies found
that mutations in genes encoding for global regulators of gene
expression were linked to neurodevelopmental disorders including
autism [5,6]. Pharmacological studies also suggested that targeting
global levels of gene expression regulation could impact neurode-
velopment. For instance, valproate, a histone deacetylase inhibitor
(HDACi), is a commonly used medication in the treatment of
seizures, mental health disorders, and cancer that impacts global
levels of gene expression regulation through chromatin based
mechanisms. When given during gestation, valproate can
adversely impact neurodevelopment in rodents and cause autism
in humans [10,11,12,13]. Thus, both genetic and pharmacological
studies suggest alterations in global levels of gene expression
regulation can interfere with normal neurodevelopment. Addi-
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that HDAC inhibitors may act by altering levels of synaptic
plasticity and in this context HDAC inhibitors have been used to
modify learning, memory, and emotional behavior underscoring
the potentially pleiotropic effects of targeting global levels of gene
expression regulation [14,15,16,17,18,19].
Addressing the impact of variability in global levels of gene
expression regulation on neurodevelopment in mice, we recently
reported that the pattern of the distribution of gene expression
levels, as assessed by variance in the distribution, accurately
predicted mouse behavior in genetically identical animals.
Specifically, we found that increased variance across the total
distribution of gene expression levels in the hippocampus
predicted increased levels of open-field exploration, a hippocampal
dependent behavior. Developmental epigenetic interventions that
modified the variance in the gene expression distribution in the
hippocampus also modified mouse behavior in tandem [20].
In the current study, we used our previously established strategy
of studying the overall pattern of the gene expression distribution
to test the hypothesis that autism would be associated with
alterations in global levels of gene expression regulation. To do
this, we compared the pattern of the gene expression distributions,
as assessed by variance across the total gene expression
distribution, in the blood of children with autism and controls
(schematic in figure 1). Further, since multiple studies associated
increased paternal age with increased rates of autism and other
neurodevelopmental disorders [21,22,23,24,25,26,27,28], we per-
formed a secondary analysis to address the hypothesis that
paternal age would be associated with changes in the pattern of
the gene expression distribution. Finally, we used traditional
approaches to gene expression analysis to examine for biological
pathways that might be causally related to changes global levels of
gene expression regulation.
Materials and Methods
Subjects
The Western Institutional Review Board approved all aspects of
the current protocol related to human subjects including written
informed consent and found that the research was conducted
according to the principles expressed in the Declaration of
Helsinki. All subjects were male. Probands and controls were all
recruited from the Phoenix area via database mailing for probands
and via flyers to scout, church, and sports groups for controls.
Blood draws for all subjects were done between the spring and
summer of 2004. Children with autism had a diagnosis of autism
by a medical professional (developmental pediatrician, psycholo-
gist, or child psychiatrist) according to the DSM-IV criteria, and
confirmation of the diagnosis by ADOS [29] and ADI-R criteria
[30]. Exclusion criteria included a significant prenatal history
(prematurity ,35 weeks, intraventricular hemorrhage, severe
asphyxia, or cerebral palsy), serious CNS abnormality, or known
genetic or metabolic disorder. In an attempt to obtain a
homogenous population of children with autism, non-classic forms
of autism were excluded, including autism with regression and
Asperger’s syndrome, a higher functioning form of autism where
individuals have language skills within the normal range. In
addition, each subject had a normal high-resolution chromosome
analysis, and a negative Fragile X DNA test. 82 children with
autism and 64 control children were included in the study. IQ
scores were not done for this study, but all individuals did have a
demonstrated impairment in language as part of the diagnostic
criteria. For our secondary analysis, paternal ages were available
for 78 children with autism and 57 controls. The group of children
with autism was significantly younger than the control group
(autism: mean - 5.5 years SD - 2.1; control: mean - 7.9 SD - 2.2,
p,.0001). Paternal age was similar between groups. The study
population was primarily Caucasian and there were no group level
differences in ethnicity.
Expression profiling
Expression profiling was performed at Translational Genomics
(TGen), a member of the NIMH Neuroscience Microarray
Consortium. Total RNA was extracted from peripheral blood
lymphocytes (PBL) within 30 minutes of the blood draw using the
Qiagen Qiaquick kit (Germantown, MD). Isolated total RNA was
double round amplified, cleaned, and biotin-labeled using
Affymetrix’s GeneChip Two-Cycle Target Labeling kit (Santa
Clara, CA) with a T7 promoter and Ambion’s MEGAscript T7
High Yield Transcription kit (Austin, TX) as per manufacturer’s
protocol. Amplified and labeled cRNA was quantified on a
spectrophotometer and run on a 1% TAE gel to check for an
evenly distributed range of transcript sizes. Twenty micrograms of
cRNA was fragmented to approximately 35–200 bp by alkaline
treatment (200 mM Tris-acetate, pH 8.2, 500 mM KOAc,
150 mM MgOAc) and run on a 1% TAE gell to verify
fragmentation. Separate hybridization cocktails were made using
15 micrograms of fragmented cRNA from each sample as per
Affymetrix’s protocol.
Two hundred microliters (containing 10 micrograms of
fragmented cRNA) of each cocktail was separately hybridized to
an Affymetrix Human Genome U133 Plus 2.0 Array for 16 h at
45 degree Celsius in the Hybridization Oven 640. The Affymetrix
Human Genome Arrays measure the expression of over 47,000
Figure 1. Schematic for determining the large-scale organiza-
tion of gene expression in the blood of children with autism
and controls. The figure displays the steps used to evaluate the large-
scale organization of gene expression in the blood of children with
autism and controls. Peripheral blood lymphocytes were purified from
the blood of children with autism (n=82) or control subjects (n=64).
Total RNA was extracted for microarray experiments with Affymetrix
Human U133 Plus 2.0 39 Expression Arrays. Array data was pre-
processed and summarized using Affymetrix Microarray Analysis Suite
5.0 (MAS 5.0) to obtain 54,675 expression levels for approximately
47,000 unique transcripts including approximately 38,500 human
genes. Expression levels were log2 transformed and the variance of
log2 transformed expression levels was determined.
doi:10.1371/journal.pone.0016715.g001
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genes. Arrays were washed on Affymetrix’s GeneChip Fluidics
Station 450 using a primary streptavidin phycoerythrin (SAPE)
stain, subsequent biotinylated antibody stain, and secondary SAPE
stain. Arrays were scanned on Affymetrix’s GeneChip Scanner
3000 7G with AutoLoader. Scanned images obtained by the
Affymetrix GeneChip Operating Software (GCOS) v1.2 were used
to extract raw signal intensity values per probe set on the array. A
scaling factor of 150 was used to normalize array signal intensity in
MAS 5.0.
Arrays were scanned over 1 day on 2 different machines. Arrays
scanned on the same machine and in the same day were
considered to be from the same scan batch. Rescanning of a
limited number of samples indicated that there were no significant
differences between machines, nonetheless, for all comparisons
groups were balanced for the scan batch. Gene expression levels
were not adjusted for possible batch effects as algorithms that
attempt to adjust for batch effects also alter the gene expression
distribution. When samples could not be prepped simultaneously
they were balanced for group membership (autism vs. control). To
statistically control for possible confounds related to scan batches
in our analysis of gene expression variance, batch number was
entered into an analysis of covariance. For traditional analysis of
gene expression, experimental groups were balanced with respect
to batch membership.
Microarray data analysis
Affymetrix .cel files were imported into Affymetrix Expression
Console version 1.1. Data was pre-processed and summarized by
Microarray Analysis Suite (MAS) 5.0 and Robust Multiarray
Analysis (RMA). For the analysis of gene expression distributions,
MAS 5.0 was used because the algorithm does not alter the gene
expression distribution, whereas, RMA utilizes quantile normal-
ization of probes prior to summarization and, therefore, has the
potential to remove group level differences in gene expression
distributions. Because of the numerous advantages in its handling
of noise in the measurement of gene expression levels and
background subtraction, RMA was used for traditional gene
expression analyses looking for specific gene expression differences
between groups. Because group level differences in the distribution
of gene expression levels between groups were found, gene
expression levels were also quantile normalized after the
summarization step for traditional gene expression analyses.
Quantile normalization adjusts all data sets such that they have
identical distribution patterns. Probe sets were then filtered for
those that were called present in at least 50 out of the 146 subjects
(n=25,146 probe sets). A p-value of .05 was used as a threshold for
significance. A fold-change of 1.1 was used as a cut off for
magnitude of change. All microarrays met manufacturers
recommended quality control criteria. Present calls ranged from
37.4% to 49%, mean 43.7%, SD 2.7%. Actin 39to59 ratios ranged
from .726 to 5.15, mean1.37, SD 0.5. There were no significant
group level differences in quality control measures.
Variance across the distribution of gene expression levels
Variance across the distribution of gene expression levels was
the primary measure used in the present study. The measure of
overall variance compresses data from the expression levels of
54,675 probe sets covering approximately 47,000 unique tran-
scripts including 38,500 human genes on the Affymetrix Human
HG-U133 Array into a single variable. We previously found that
overall variance in gene expression levels in the hippocampus of
mice accurately predicted hippocampal-dependent behavior[20].
To calculate overall variance, gene expression levels for all 54,675
probe sets on the Affymetrix Human HG-U133 Array were log2
transformed. Variance in log2 transformed expression levels was
calculated across all 54,675 probe sets in the total distribution as
the average of the squares of the deviations from the mean.
Pathway Analysis
DAVID (david.abcc.ncifcrf.gov) Functional Annotation Bioin-
formatics Microarray Analysis[31,32] was used to assess gene lists
for enriched biological themes. A user supplied background list
was uploaded which consisted of the list of all probe sets that were
called present by Affy MAS 5.0 in at least 50 of 146 subjects
(n=25,146). Lists of significant probe sets met the following
criteria: present in at least 50 subjects, p,.05, and absolute fold
change of at least 1.1-fold.
Statistical Cross Validation
We found significant differences in variance in gene expression
between children with autism and controls. When the paternal age
of the control father was considered it was found that variance in
gene expression of children with autism was only significantly
different from children of younger fathers. Additionally, we found
that variance in gene expression was significantly different between
children of older fathers and children of younger fathers. To
validate these findings we subdivided our data sets into 6
subgroups to allow for within study ‘‘replications’’. In all cases
subgroups of the same type (e.g. autism, younger father, older
father) were equally balanced for paternal age and scan batch. The
validation sets were as follows: Autism1 (n=41), Autism2 (n=41),
Control young father1 (n=14), Control young father2 (n=14),
Control old father1 (n=14), Control old father2 (n=14), Control
1 (n=28 - combination of control young father1 and control old
father1), and Control 2 (n=28 - combination of control young
father2 and control old father2)(figure S1 and table S1).
Transcription inhibitor dataset
In order to assess for changes in gene expression variance in
response to globally targeting transcription, we downloaded a
publically available dataset in which a new class of transcription
inhibitors, sappyrins, were compared to actinomycin D. The
microarray study analyzed gene expression in A549 human lung
cancer cells that were treated with transcriptional inhibitors[33]:
[actinomycin D (5 ug/mL), sapphyrin (low – 1.5 uM), sapphyrin
(high – 2.5 uM), or mannitol (5%) as a control]. Cel files were
downloaded from the Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo) public database. The microarrays used in
the transcription inhibitor study were the same used in the current
study, Affymetrix Human Genome U133 Plus 2.0 Array.
Microarray data was pre-processed and summarized as described
above using Expression Console and the MAS 5.0 algorithm.
Statistical Analyses
JMP8 and Statview software (SAS, Cary, NC) were used for
statistical analyses. The statistical analyses used in the study are
listed below.
Tests of normality
To determine if parametric tests were appropriate, the Shapiro-
Wilk Test was performed for the primary measures: variance in
gene expression and paternal age. When assessed across the entire
study or across all control subjects, variance in gene expression was
not normally distributed, but was normally distributed within
experimental groups: 1) autism, 2) children of older fathers, and 3)
children of younger fathers. Paternal age was normally distributed
Autism Changes Global Gene Expression Regulation
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tal groups: 1) autism and 2) controls. Based on these analyses of
normality, parametric tests were used when appropriate.
Pearson’s correlation coefficient (r)
Pearson’s correlation coefficient (r) between two variables is
defined as the covariance of the two variables divided by the
product of their standard deviations. The square of the Pearson’s
correlation coefficient (R
2) estimates the proportion of variance in
a dependent variable (e.g. overall variance) that is accounted for by
an independent variable (e.g. paternal age). Fisher’s transforma-
tion was used to calculate a p-value from the Pearson’s r. For our
analyses we considered a p-value of .05 to be statistically
significant.
Spearman’s rank correlation (rho)
Spearman’s rank correlation assesses how well the relationship
between two variables can be described using a monotonic
function. It is used to assess the relationship between 2 variables
when data is not normally distributed.
Unpaired Student’s T-tests
Compares two groups of normally distributed data to test
whether the means of the distributions are different. The p-value
represents the probability that the distributions are actually
different. For our analyses we considered a p-value of .05 to be
statistically significant.
Analysis of covariance
Analysis of covariance was used to examine the potential
confounding effects of subject age and scan batch on a significant
association of autism with decreased overall variance. Variance was
the dependent variable, diagnosis (21= autism, +1= control),
subject age, and scan batch (21= batch 1, +1= batch 2). All
possible interaction terms were also included in the model. For our
analyses we considered a p-value of .05 to be statistically significant.
Chi square
An internet based 262 chi square contingency table (http://
www.graphpad.com/quickcalcs/contingency1.cfm) was used to
assess for a significant overlap between gene lists. A chi-square
with Yates correction was used to calculate chi squared and a two-
tailed p-value.
Results
Decreased overall variance in log-transformed measures
of gene expression predicts the diagnosis of autism
(figures 1 and 2)
We used microarrays to measure the expression levels of greater
than 47,000 unique transcripts including 38,500 well-character-
ized human genes using the Affymetrix Human U133 Plus 2.0
microarray with purified RNA from peripheral blood lymphocytes
from each of 82 children with sporadic cases of autism and 64
control subjects (figure 1). In contrast to comparing the expression
levels of individual genes, we compared the pattern of the overall
distribution of gene expression levels between children with autism
and controls. Measurement of the variance in the distribution of
gene expression levels assessed for differences at the global level of
gene expression regulation. To obtain a normal-like distribution,
gene expression levels were log2-transformed. The overall
variance of the total distribution was measured for each
microarray (schematic in figure 1). The distribution of gene
expression levels on microarrays from individuals with autism had
a decreased variance when compared to microarrays from controls
(figure 2, p=.006, parameter estimate =2.45 Std Dev lower in
autism).
Because the group of children with autism was significantly
younger than the control group (autism: mean - 5.5 years SD - 2.1;
control: mean - 7.9 SD - 2.2, p,.0001), we tested whether subject
age had an effect on the relationship between diagnosis and overall
variance. An analysis of covariance (ANCOVA) demonstrated that
even when controlling for subject age, variance in gene expression
continued to be significantly decreased by the same amount in the
blood of children with autism compared to controls (p=.018,
parameter estimate =2.45 Std Dev lower in autism). When scan
batch was included with subject age in the ANCOVA the results
also remained significant (p=.03, parameter estimate =2.42 Std
Dev lower in autism). Importantly, parameter estimates for the
relationship of diagnosis to variance were virtually unchanged in
the ANCOVAs indicating that increasing p-values were related to
increases in the degrees of freedom in the analysis, and not to a
decreased association.
Increased paternal age is associated with decreased
overall variance in gene expression levels (figure 3)
Previous work in mice indicated that factors or interventions
that modified mouse hippocampal-dependent behavior also
modified overall variance in the predicted direction [20]. We
hypothesized, therefore, that factors that modified risk for autism
in the general population might alter the variance in gene
expression in a manner that resembled the variance in gene
expression in children with autism. Paternal age was found in
multiple studies to be a risk factor for autism and other
neurodevelopmental disorders such as schizophrenia and mental
retardation [26,28,34,35]. We found that in controls, but not in
children with autism, overall variance in gene expression was
significantly and negatively associated with paternal age (Pearson
r=2.283, R
2=.08, p=.03, parameter estimate =2.054 Std
Figure 2. Overall variance in gene expression in peripheral
blood lymphocytes (PBL) was decreased in children with
autism. We used microarrays to measure the expression levels of
greater than 47,000 transcripts including 38,500 well-characterized
human genes using the Affymetrix Human U133 Plus 2.0 microarray on
RNA from peripheral blood lymphocytes from each of 82 children with
autism and 64 control subjects. Microarrays showed no group level
differences in quality control measures. Microarray expression levels
were log-transformed and the overall variance was calculated across the
total distribution of expression levels on each microarray. Variance in
gene expression was significantly decreased in the blood of children
with autism (p=.006). Error bars represent standard error.
doi:10.1371/journal.pone.0016715.g002
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covariance (ANCOVA) results remained significant after control-
ling for subject age (p=.046, parameter estimate =2.052 Std
Dev/year of paternal age) and scan batch (p=.03, parameter
estimate =2.055 Std Dev/year of paternal age). When both
potential confounds were entered into the model the parameter
estimate remained unchanged, but the p-value was slightly above
.05 (p=.056, parameter estimate =2.052 Std Dev/year of
paternal age). Thus, paternal age-related changes in gene
expression variance in control subjects were similar in direction
to autism-related changes in variance. We also assessed the
relationship between paternal age and variance in gene expression
using Spearman rank correlation (Spearman rho =2.274, rho
corrected for ties =2.281, p=.04, p corrected for ties =.036).
The use of a non-parametric test addressed any potential concerns
about the effects of possible outliers (though no values were greater
than 3 standard deviations from the mean) and of problems arising
from the use of non-normal data distributions with parametric
tests. The measurement of variance in the distribution of gene
expression levels was not normally distributed within the group of
control children.
Because increased paternal age and autism were both negatively
related to overall variance in gene expression, it was predicted that
the overall variance in gene expression for children of older fathers
would be similar to that in children with autism. To confirm this
hypothesis, we performed a median split of subjects by paternal
age (median =31 years) and assessed for differences in overall
variance in gene expression between children with autism and
controls in groups of children from older and younger fathers. As
predicted, we found that the overall variance was the same in the
blood of children from older fathers as in the blood of children
with autism from fathers of any age (figure 3b). We found that the
association of autism with decreased overall variance was only
found in children of younger fathers (p=.0007) (figure 3b). As
expected from the negative correlation, in the median split
analysis, variance in gene expression in the blood of control
children of older fathers was significantly decreased compared to
control children of younger fathers (p=.03) (figure 3b).
Decreased variance in gene expression is related to the
down-regulation of genes involved in the regulation of
transcription (figure 4 and tables S2–S4)
To evaluate for a possible mechanism underlying decreased
variance in gene expression in the blood of children with autism or
from older fathers, we analyzed for specific gene expression
differences between study groups. Gene expression patterns in the
blood of children with autism and control children of older fathers
were compared to gene expression patterns in the blood of control
children of younger fathers. First, it was noted that in the blood of
children with autism and children of older fathers, there were
many more significantly down-regulated genes than up-regulated
genes (figure 4a). In the comparison of children with autism to
children of younger fathers, there 2,093 genes that were
significantly down-regulated by at least 1.1-fold and only 641
genes that were up-regulated. In the blood of children of older
fathers compared to children of younger fathers there were 1,476
down-regulated and 764 up-regulated genes. To determine if the
same genes were up or down-regulated in children with autism
and children of older fathers, we compared lists of genes and
assessed the degree of overlap. The overlaps between genes that
were down or up-regulated in children with autism and children of
older fathers were highly significant. There were 593 genes that
were down-regulated in both children with autism and children of
older fathers (figure 4b) (chi square 2,071, p,.000001) and 145
genes that were both up-regulated in both comparisons (chi square
849, p,.000001).
Figure 3. Increased paternal age at birth is negatively
associated with overall variance in gene expression in
peripheral blood lymphocytes (PBL) of normal children.
Paternal age at birth was found in multiple studies to be a risk factor
for autism [26,28,34,35]. Previous work indicated that factors or
interventions that modified mouse hippocampal-dependent behavior
also modified the overall variance in gene expression in the predicted
direction. In controls (figure 3a) but not in children with autism (not
shown), overall variance in log-transformed measures of gene
expression was significantly and negatively associated with paternal
age at birth (r=-.283, R
2=.08, p=.03, number of subjects =57). For the
evaluation of paternal age effects, paternal ages were available for 78
children with autism and 57 control children. To directly compare
overall microarray variance in children with autism to children of older
fathers, we divided subjects by the median paternal age at birth in our
study (31 years) and created 2 groups: 1) children from younger fathers
(less than 31 years) (65 subjects: 30 controls and 35 children with
autism); and 2) children from older fathers (31 years or older) (70
subjects: 27 controls and 43 children with autism). We compared mean
levels of overall variance between children with autism and controls of
older and younger fathers. As predicted, we found that overall variance
was the same in children of older fathers and children with autism with
fathers of any age (figure 3b). We found that the association of autism
with decreased overall variance was only found in children of younger
fathers and represented a difference of .78 standard deviations within
our sample (p=.0007) (figure 3b). Error bars represent standard error.
doi:10.1371/journal.pone.0016715.g003
Autism Changes Global Gene Expression Regulation
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16715To determine if these overlapping genes were enriched for
particular biological pathways, DAVID was used to perform
pathway analysis. As background, we used the 25,146 probe sets
that were above our background cut-off requiring that they were
called present in at least 50 out of 146 samples. Pathway analysis
indicated that multiple pathways associated with transcriptional
regulation and supported by multiple independent databases, e.g.
GOTERM, BIOCARTA, OMIM disease, etc., were enriched
Figure 4. Down-regulated genes are enriched for biological pathways related to transcription and zinc. Traditional gene expression
analyses were performed. Microarrays were processed and summarized using RMA. Post-summarization gene expression levels were quantile
normalization because of the known group level differences at the level of the distribution. Probe sets were filtered for those that were called present
in at least 50 of 146 samples. Figure 4a shows that there were more down-regulated than up-regulated genes in the blood of children with autism
and children of older fathers when compared to children of younger fathers. 4b shows a very significant overlap (chi-squared =2,085, p,.00001) of
down-regulated genes in children with autism and children of older fathers. Figure 4c demonstrates that overlapping down-regulated genes are
enriched for biological pathways associated with transcription and zinc.
doi:10.1371/journal.pone.0016715.g004
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children with autism and children of older fathers (figure 4c).
Importantly, we also found that the same pathways were enriched
in the lists of genes that were significantly down-regulated but not
shared between children with autism and children of older fathers
(Table S2), i.e. there was overlap in biological pathways even when
the specific genes were not identical. Significant pathways
associated with up-regulated genes (Table S3) were fewer in
number and did not appear to offer any mechanistic understand-
ing for global changes in gene expression regulation. Pathway
analysis of gene lists obtained using more stringent cutoffs (51%
present and a 1.25-fold change) highlighted many of the same
pathways related to transcriptional regulation even though the
gene lists were much shorter (72 compared to 593 genes in the list
of overlapping down-regulated genes) (table S4).
Cross-validation (figure S1 and table S1)
To evaluate the robustness of our findings, experimental groups
were sub-divided to perform statistical cross-validation. For
instance, the group of 82 children with autism was divided into
2 groups of 41 children that were balanced for paternal age and
microarray scan batch (Autism1 and Autism2), the group of
children with older fathers (.30 years old) was divided into 2
groups of 14 children (Old father1 and Old father2), and the group
of children of younger fathers (, or =30 years old) was divided
into 2 groups of 14 children (Young father1 and Young father2).
With respect to variance in gene expression (Figure S1), cross-
validation of autism vs. children of young fathers remained
significant in both analyses, whereas the difference between
children of older fathers and children of younger father was no
longer significant (Figure S1). Cross-validation using Pearson
correlations found that paternal age was significantly correlated
within the Conrol1 group (p=.02) but not in the Control2 group.
The lack of significance in the cross-validation of paternal age
effects appeared to be related to decreased power because of the
smaller number of subjects per group in the analysis of age effects,
as the means of the subgroups were similar to those of children
with autism (figure S1).
Cross-validation of pathway analysis indicated that these
findings were highly robust. Significant gene lists from subgroups
(Autism1 vs. Young father1, Autism2 vs. Young father2, Old
father1 vs. Young father1, and Old father2 vs. Young father2)
indicated that in all cases, significantly down-regulated genes in
children with autism or children of older fathers were enriched for
genes involved in transcription (Table S1). It was also noted in
these analyses that, in all cases, sets of down-regulated genes were
also enriched for zinc finger C2H2 proteins and for genes involved
in zinc pathways. Zinc has a well-documented role in neurode-
velopment[36,37,38] and also plays any important role in the
stabilization of many proteins involved in transcription[38],
suggesting that zinc-mediated effects on transcription may be
particularly important in contributing to global effects on gene
expression.
Inhibition of transcription leads to a decreased variance
in gene expression (figure 5)
Pathway analysis showed that regulators of transcription were
enriched in the subset of genes that were down-regulated in
children with autism and control children of older fathers. This
suggested that dysregulation of transcription might be a mecha-
nism underlying the decreased variance in gene expression in these
groups of children. To explore this hypothesis, we used a publically
available dataset to examine whether inhibition of transcription
can lead to decreased variance in gene expression. In the gene
expression study, a human lung cancer cell line, A549, was treated
with transcription inhibitors for four hours. Treatment with high
levels of sapphyrin (n=3, p=.07), a new class of transcription
inhibitor, or actinomycin D (n=3, p=.04) led to a decrease in
variance in gene expression when compared to control treatment
with mannitol (figure 5). Low levels of sapphyrin had no effect on
variance in gene expression. When study groups were pooled to
increase power, actinomycin D (n=3) + high sapphyrin (n=3) vs.
low sapphyrin (n=3) + mannitol, (n=3), the effect of transcription
inhibition was a highly significant decrease in variance in gene
expression (p=.003) (figure 5).
Discussion
Studying the variance in the distribution of gene expression
represents a new approach to gene expression analysis. Because
changes in a limited number of genes could not account for a
change in the shape of the entire gene expression distribution,
changes in variance suggest alterations at global levels of gene
expression regulation. This ‘‘birds-eye view’’ of gene expression
levels contrasts with gene-centered approaches that seek to identify
specific genes or pathways that differ between groups. While gene
specific approaches are useful they may miss changes occurring at
the global level of gene expression regulation. The two
approaches, therefore, represent distinct yet potentially compli-
mentary approaches to understanding the full magnitude of effects
on gene expression regulation. Here we used our novel approach
Figure 5. Transcription inhibitors lead to decreased variance in
gene expression. Gene expression data from a publically available
dataset show that treatment of a lung cancer cell line with actinomycin
D and a high dose of sapphyrin results in decreased variance in gene
expression compared to treatment with mannitol or a low dose of
sapphyrin. Error bars represent standard error.
doi:10.1371/journal.pone.0016715.g005
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variance in gene expression levels with the diagnosis of autism and
a risk factor for autism, increased paternal age. We complimented
this global approach with gene specific analyses that indicated that
changes in global levels of gene expression regulation might be
related to large-scale changes in transcriptional regulation. Finally,
we reinforced the potential role of transcription regulation by
demonstrating with a publically available dataset that inhibition of
transcription could, in fact, lead to decreased variance in the
distribution of gene expression levels.
Global levels of gene expression regulation may be particularly
important in understanding the pathological basis of diseases such
as autism where multiple systems are affected. This is true because
alterations at the global level of gene expression regulation could
be shared across systems even when the tissue specific genes
affected by these global changes were different. For instance, in the
current study, even though gene expression patterns in the brain
and blood are known to be different, it is possible that in the brains
of children with autism, variance in gene expression is decreased as
it is in the blood. Thus, it is possible that a common mediator, a
change at the global level of gene expression regulation, could
offer a unifying explanation for multi-systemic effects of disease. By
understanding that global levels of gene expression regulation can
be disrupted in disease, it becomes clear that targeting global levels
of gene expression regulation might also be therapeutic, an idea
strongly supported by successful treatments such as HDAC
inhibitors in mental health disorders and cancer[39]. Interestingly,
HDAC inhibitors are known to affect immune, endocrine, and
neurological systems, thus giving added support to the idea that
globally targeting gene expression regulation can affect multiple
systems [14,39,40,41].
The association of paternal age with overall variance in gene
expression in the blood of healthy controls is interesting. In our
study, decreased variance in gene expression was a risk factor for
the diagnosis of autism. That another well established risk factor
for autism, increased paternal age, was associated with a similar
decrease in variance raises the interesting possibility that the
associated increased risk of autism in children of older fathers
could be mediated by changes in global levels of gene expression
regulation or by paternally transmitted age-related factors that are
linked to changes in the global regulation of gene expression. In
other words, an effect on global levels of gene expression
regulation transmitted by older fathers might act to increase the
likelihood that neurodevelopmental abnormalities will occur and
thus increase the rates of autism in children of older fathers.
Determining whether this hypothesis is correct would require a
large-scale prospective study in which statistical models assessed
whether increased rates of autism in children of older fathers were
statistically mediated by effects on variance in gene expression.
The association of variance in gene expression with paternal age
is also interesting because it suggests that fathers may transmit
factors influencing global levels of gene expression regulation in
offspring. Paternal age has previously been associated with another
genomic phenotype, increased telomere length, indicating that, in
principal, global genomic properties can be sensitive to paternal
age[42,43]. Possible mechanisms for the transmission of factors
influencing global levels of gene expression regulation are
suggested by the association of aging with de novo germ line
mutations and global changes in DNA methylation [44]. Each of
these properties, if paternally transmitted to offspring, could
influence global regulation of gene expression. Given the vast
number of gene expression changes that occur throughout
development, understanding how global effects on gene expression
regulation may be transmitted across the germ line to ultimately
influence the overall variance in gene expression in differentiated
cells could prove crucial to our understanding of how general
genomic properties are transmitted to and influence the function
of very different cell types.
The parallels of the current study to our work in mice also bear
discussion. We found in mice that epigenetic factors acted during
early brain development to elicit changes in adult behavior that
were accompanied by changes in the variance in gene expres-
sion[20]. In a separate study, we found that the same hippocampal-
dependent behaviors were paternally transmitted to offspring even
though fathers were not present for rearing suggesting an epigenetic
germline transmission of factorsthat influencedbraindevelopment,
behavior, and variance in gene expression [45]. In autism,
paternally transmitted epigenetic factors related to age have also
been implicated [23,26] and in the current study paternal age was
associated with differences in the variance in gene expression in the
general population. Though much further study is need, both lines
of work suggest the presence of epigenetic paternally transmitted
factors in both mice and humans that can influence brain
development and global levels of gene expression regulation.
Alterations in the overall variance in gene expression in
peripheral blood lymphocytes are also of interest. Children with
autism have immunological abnormalities and it has been
previously reported that gene expression differences were found in
immune cells of children with autism [8,9,46]. More surprising was
the finding in this study that increased paternal age was associated
with the same global gene expression phenotype and specific
alternations in transcription-related biological pathways in healthy
controls as was associated with the diagnosis of autism. As discussed,
a relationship to paternal age suggests that factors influencing global
levels of gene expression regulation may be transmitted across the
germ line. Additionally, findings in the blood suggest the possibility
for effects of paternal age on immune function. An association of
increased paternal age with immune function is suggested by a
common link between increased paternal age and mental disorders
such as schizophrenia, bipolar disorder, and autism, and the
association of these disorders with a common set of immune
abnormalitiesthat includesincreasesinpro-inflammatorycytokines,
IL-1beta and IL-6[47,48].Amore generalized effect ofpaternalage
on immune function seems plausible. Increased paternal age has
been associated with impairments in neurocognitive ability during
infancy and childhood in the general population [34] and with an
increasein‘‘externalizing’’behaviorsinthe generalpopulation[49].
Given the links between paternal age, neurodevelopomental
disorders, and immune function, it seems that paternal age might
also have a more generalized effect on immune function as it was
found to have on neurodevelopment.
Finally, traditional approaches to gene expression analysis
suggested a possible mechanism for the changes in gene expression
variance.Wefoundenrichmentforgenesinvolvedintranscriptional
regulation in genes that were down-regulated with respect to
paternal age and autism. Analysis of the effects of transcription
inhibition on gene variance was supportive of the hypothesis that
down-regulation of transcriptional regulators may account for the
decreased variance in gene expression in the current study. Also of
interest we found enrichment for genes regulated by zinc, an
important component of many transcription factors. Since it has
been demonstrated that neuronal plasticity is often transcription
dependent [50,51], it seems plausible that an alteration in the
general regulation of transcription could adversely impact neuro-
development. Though further study is needed, the suggestion by
pathway analysis of transcription dysregulation in autism is
consistent with genetic findings that mutations in general transcrip-
tion factors are associated with neurodevelopmental disorders
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interest given the recent report of a decreased zinc/copper ratio in
children with autism spectrum disorders [52].
Multiple lines of evidence including genetic linkage [5,6],
pharmacological studies [10,11,12,53], and the associations
observed in the current study suggest that variations in global
levels of gene expression regulation may contribute to the risk for
neurodevelopmental disorders including autism. An association of
variance in gene expression with paternal age in healthy controls
suggests that factors influencing global levels of gene expression
regulation may be transmitted across the germ line. Findings in
immune cells suggest that global levels of gene expression
regulation may impact systems other than the brain. Finally,
pathway analysis suggests that altered regulation of transcription
may underlie decreased variance and may increase risk for autism.
A more thorough understanding of the mechanisms and the
biological impact of the reported associations with overall variance
in gene expression represent important areas for future research.
Supporting Information
Figure S1 Cross-validation. Figure describes the work flow
used for cross-validation. Briefly, experimental groups were
divided in half to create 6 subgroups that were balance for scan
batch (autism1, autism2, children of older fathers1, children of
older fathers2, children of younger fathers1, children of younger
fathers2). a) Shows cross-validation of changes in gene expression
variance. The means of autism1, autism2, older father1, and older
father 2 are lower than the means of younger father 1 and 2, but
only the autism subgroups are significantly different. b) Demon-
strates a significant overlap between down-regulated genes in
autism1 vs. young father1 and autism2 vs. young father2 (chi-
squared =866.6, p,.00001). c) Demonstrates a significant overlap
in down-regulated genes in old father1 vs. young father1 and old
father2 vs. young father2 (chi-squared =10.4, p=.0013).
(TIFF)
Table S1 Cross-validation of pathway analysis of down-
regulated genes. Pathway analysis was done on significant gene
lists (p,.05, absolute fold change .1.1) from cross-validation
datasets (autism1 vs. younger father1, autism2 vs. young father2,
old father1 vs. young father1, old father2 vs. young father 2). The
table illustrates that cross-validation datasets highlighted the same
enrichment of biological pathways related to transcription and
zinc.
(PDF)
Table S2 Non-overlapping down-regulated genes. Path-
way analysis was done on significant gene lists (p,.05, absolute
fold change .1.1) of genes that were down-regulated in autism or
in children of older fathers and not overlapping with the other
group.
(PDF)
Table S3 Up-regulated Pathways. Pathway analysis was
done on significant gene lists (p,.05, absolute fold change .1.1) of
genes that were up-regulated in autism or in children of older
fathers.
(PDF)
Table S4 Pathway analysis with increased stringency
for gene list selection. Pathway analysis was done on
significant gene lists (p,.05, absolute fold change .1.25, and
present calls .51%) of genes that were down-regulated in autism
and in children of older fathers. Table shows that the same
pathways were enriched as with lower stringency gene list
selection.
(PDF)
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